M
Marc R. Theoret
Researcher at Food and Drug Administration
Publications - 130
Citations - 7246
Marc R. Theoret is an academic researcher from Food and Drug Administration. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 30, co-authored 96 publications receiving 5389 citations. Previous affiliations of Marc R. Theoret include Center for Drug Evaluation and Research & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
Willem W. Overwijk,Marc R. Theoret,Steven E. Finkelstein,Deborah R. Surman,Laurina A. de Jong,Florry A. Vyth-Dreese,Trees A. M. Dellemijn,Paul A. Antony,Paul J. Spiess,Douglas C. Palmer,David M. Heimann,Christopher A. Klebanoff,Zhiya Yu,Leroy N. Hwang,Lionel Feigenbaum,Ada M. Kruisbeek,Steven A. Rosenberg,Nicholas P. Restifo +17 more
TL;DR: It is found that tumor growth and lethality were unchanged in mice even after adoptive transfer of large numbers of T cells specific for an MHC class I–restricted epitope of the self/tumor antigen gp100, illustrating that adoptive transferof T cells and IL-2 can augment the function of a cancer vaccine.
Journal ArticleDOI
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
Luca Gattinoni,Christopher A. Klebanoff,Christopher A. Klebanoff,Douglas C. Palmer,Claudia Wrzesinski,Keith W. Kerstann,Zhiya Yu,Steven E. Finkelstein,Marc R. Theoret,Steven A. Rosenberg,Nicholas P. Restifo +10 more
TL;DR: The findings suggest that the current methodology for selecting T cells for transfer is inadequate and provide new criteria for the generation and the screening of optimal lymphocyte populations for adoptive immunotherapy.
Journal ArticleDOI
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
Christopher A. Klebanoff,Steven E. Finkelstein,Deborah R. Surman,Michael K. Lichtman,Michael K. Lichtman,Luca Gattinoni,Marc R. Theoret,Navrose Grewal,Paul J. Spiess,Paul A. Antony,Douglas C. Palmer,Yutaka Tagaya,Steven A. Rosenberg,Thomas A. Waldmann,Nicholas P. Restifo +14 more
TL;DR: It is demonstrated that IL-15 can improve the in vivo antitumor activity of adoptively transferred CD8+ T cells, which provides several avenues for improving adoptive immunotherapy of cancer in patients.
Journal ArticleDOI
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali,Zhiya Yu,Marc R. Theoret,Dhanalakshmi Chinnasamy,Nicholas P. Restifo,Steven A. Rosenberg +5 more
TL;DR: Normalization of tumor vasculature through disruption of the VEGF/VEGFR-2 axis can increase extravasation of adoptively transferred T cells into the tumor and improve ACT-based immunotherapy, providing a rationale for the exploration of combining antiangiogenic agents with ACT for the treatment of patients with cancer.
Journal ArticleDOI
High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens
Richard A. Morgan,Mark E. Dudley,Yik Y. L. Yu,Zhili Zheng,Paul F. Robbins,Marc R. Theoret,John R. Wunderlich,Michael S. Hughes,Nicholas P. Restifo,Steven A. Rosenberg +9 more
TL;DR: The results suggest that lymphocytes genetically engineered to express anti-gp100 TCR may be of value in the adoptive immunotherapy of patients with melanoma.